Loading...
•
Mar 31, 2023
Generation Bio Q1 2023 Earnings Report
Generation Bio reported first quarter 2023 financial results, highlighted by a strategic collaboration with Moderna and a cash balance expected to fund operations into 2025.
Key Takeaways
Generation Bio reported a net loss of $32.1 million for the first quarter of 2023. The company's cash balance of $288.6 million is expected to fund operations into 2025. A strategic collaboration with Moderna was also announced.
Entered into a strategic collaboration with Moderna for liver disease programs and immune cell targeting.
Factor VIII expression data in non-human primates for the hemophilia A program is expected in 2023.
Cash balance of $288.6 million as of Q1 2023 is expected to fund operations into 2025.
Received an additional $47.5 million from the Moderna collaboration in the second quarter of 2023.
Forward Guidance
The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...